Blood Test May Help Predict Lung Cancer Risk Years Before Diagnosis
Scientists have discovered a blood-based protein pattern that may help identify individuals at risk of developing lung cancer up to five years before the disease is diagnosed. This finding could support earlier detection compared to current risk assessment methods that mainly rely on age and smoking history.
The study, published in a leading scientific journal, suggests that environmental factors such as air pollution may contribute significantly to cancer development. Exposure to harmful pollutants from traffic emissions, industrial sources, coal burning, and tobacco smoke may create long-term inflammation in the lungs, which can activate abnormal cells over time.
Researchers analyzed blood samples from more than 48,000 participants in a large UK-based health database. Using advanced machine learning techniques, they identified a group of 14 proteins linked to a higher likelihood of developing lung cancer within five years.
To improve accuracy, the model also considered additional risk factors such as age, smoking status, and previous lung disease history. The results were validated across multiple international datasets and showed consistent patterns in people who later developed lung cancer, including non-smokers exposed to environmental risks.
Inflammation May Play a Key Role
The study suggests that the identified protein pattern reflects early inflammatory changes in the lungs rather than the presence of an actual tumor. This indicates that long-term inflammation may be an important early driver of lung cancer.
Researchers also found links between this inflammatory state and chronic lung conditions such as COPD and pulmonary fibrosis, suggesting a shared underlying biological process.
Further analysis indicated that specific immune system pathways, particularly those involving inflammatory signaling molecules, may contribute to the activation of dormant mutated cells in lung tissue.
Potential for Early Prevention Strategies
In experimental studies, blocking certain inflammatory signals was shown to reduce the development of pre-cancerous changes in lung tissue. This raises the possibility that targeted treatments could one day help reduce cancer risk in high-risk individuals.
Researchers also revisited previous clinical trial data and found that individuals with higher levels of the identified protein signature showed a significantly reduced risk of lung cancer when treated with specific anti-inflammatory medication.
Experts believe this approach could lead to more personalized prevention strategies, where only high-risk individuals receive preventive treatment instead of broad population-based interventions.
Expert Opinions
Medical experts involved in the research say the findings support the idea that lung cancer risk may be detectable years before diagnosis through blood testing.
They believe this could eventually help doctors identify high-risk individuals earlier and reduce the number of cases diagnosed at advanced stages, where treatment options are more limited.
